Study Description
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab
compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top
of standard-of-care (SoC) treatment in participants with active systemic lupus
erythematosus (SLE). A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study
to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of
standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 1)
Interventions
Ianalumab
Placebo
Eligibility Criteria
Inclusion Criteria:
- Male and female participants aged 12 years or older at the time of screening, or
limited to 18 years or older in European Economic Area countries and other countries
where inclusion of participants below 18 years is not allowed.
- Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against
Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria
at least 6 months prior to screening.
- Elevated serum titers at screening of anti-nuclear antibodies ≥ 1:80 as determined
by a central laboratory with a SLE-typical fluorescence pattern.
- Currently receiving CS and/or anti-malarial treatment and/or another
disease-modifying antirheumatic drug (DMARD) as specified in the protocol.
- SLEDAI-2K criteria at screening: SLEDAI-2K score ≥ 6 points, excluding points
attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome"
- BILAG-2004 disease activity level at screening of at least 1 of the following:
- BILAG-2004 level 'A' disease in ≥ 1 organ system, Or
- BILAG-2004 level 'B' disease in ≥ 2 organ systems
- Weigh at least 35 kg at screening
Exclusion Criteria:
- Prior treatment with ianalumab
- History of receiving following treatment: I) high dose CS, calcineurin inhibitors,
JAK or other kinase inhibitors or other DMARD (except as listed in inclusion
criteria) administered within 12 weeks prior to screening. II) cyclophosphamide or
biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I
interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell
activating factor (BAFF)-targeting agents administered within 24 weeks prior to
screening; belimumab administered within 12 weeks prior to screening. III) any B
cell-depleting therapies, other than ianalumab administered within 36 weeks prior to
randomization or as long as B cell count is less than the lower limit of normal or
baseline value prior to receipt of B cell-depleting therapy (whichever is lower).
IV) Traditional Chinese medicines administered within 30 days prior to
randomization.
- Active viral, bacterial or other infections requiring intravenous or intramuscular
treatment for clinically significant infection
- Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Evidence of active tuberculosis infection
- History of primary or secondary immunodeficiency, including a positive human
immunodeficiency virus (HIV) test result at screening
- Any one of the following abnormal laboratory values prior to randomization
- Platelets < 25000/mm^3 (< 25 x 10^3/μL)
- Hemoglobin (Hgb) < 8.0 g/dL (< 5 mmol/L), or < 7.0 g/dL (< 4.3 mmol/L) if
related to participant's SLE such as in active hemolytic anaemia
- Absolute neutrophil count (ANC) (< 0.8 x 10^3/ μL)
- Severe organ dysfunction or life-threatening disease at screening
- Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or
equivalent using spot urine protein creatinine ratio, or serum creatinine greater
than 2.0 mg/dL (176.84 µmol/L), or requiring immune-suppressive induction or
maintenance treatment at screening
- Receipt of live/attenuated vaccine within a 4-week period before first dosing
- Any uncontrolled, co-existing serious disease, which in the opinion of the
investigator will place the participant at risk for participation or interfere with
evaluation for SLE-related symptoms
- Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or
chronic treatment with systemic CS
- History of malignancy of any organ system other than localized basal cell carcinoma
of the skin or in situ cervical cancer
- Pregnant or nursing (lactating) women.
- Women of child-bearing potential (WOCBP), defined as all women physiologically
capable of becoming pregnant, unless they are using highly effective methods of
contraception while on study treatment and for 6 months after stopping of
investigational drug.
- Any surgical, medical, psychiatric or additional physical condition that may
jeopardize participation in this study
Novartis Investigative Site
Recruiting
Niteroi,RJ,24020 096,Brazil
Novartis Investigative Site
Recruiting
Rio de Janeiro,RJ,22211 230,Brazil
Novartis Investigative Site
Recruiting
Barretos,Sao Paulo,14784 400,Brazil
Novartis Investigative Site
Recruiting
Salvador,BA,40150 150,Brazil
Novartis Investigative Site
Recruiting
Sao Paulo,SP,01244-030,Brazil
Novartis Investigative Site
Recruiting
Vitoria,ES,29055 450,Brazil
Novartis Investigative Site
Recruiting
Sao Paulo,SP,04038-002,Brazil
Novartis Investigative Site
Recruiting
Belo Horizonte,MG,30150-221,Brazil
Novartis Investigative Site
Recruiting
Salvador,40301-155,Brazil
Novartis Investigative Site
Recruiting
Curitiba,PR,80030-110,Brazil
Novartis Investigative Site
Recruiting
Ruse,7002,Bulgaria
Novartis Investigative Site
Recruiting
Sofia,1680,Bulgaria
Novartis Investigative Site
Recruiting
Plovdiv,4002,Bulgaria
Novartis Investigative Site
Recruiting
Vancouver,British Columbia,V5z 1l7,Canada
Novartis Investigative Site
Recruiting
Hamilton,Ontario,L8n 3z5,Canada
Novartis Investigative Site
Recruiting
Toronto,Ontario,M5t 2s8,Canada
Novartis Investigative Site
Recruiting
Rimouski,Quebec,G5l 5t1,Canada
Novartis Investigative Site
Recruiting
Beijing,100730,China
Novartis Investigative Site
Recruiting
Nanjing,Jiangsu,210008,China
Novartis Investigative Site
Recruiting
Guangzhou,Guangdong,510000,China
Novartis Investigative Site
Recruiting
Shanghai,200040,China
Novartis Investigative Site
Recruiting
Suzhou,Jiangsu,215004,China
Novartis Investigative Site
Recruiting
Guangzhou,Guangdong,510080,China
Novartis Investigative Site
Recruiting
Shanghai,200127,China
Novartis Investigative Site
Recruiting
Nanchang,Jiangxi,330006,China
Novartis Investigative Site
Recruiting
Shantou,Guangdong,515041,China
Novartis Investigative Site
Recruiting
Zhejiang,315016,China
Novartis Investigative Site
Recruiting
Pingxiang,Jiangxi,337000,China
Novartis Investigative Site
Recruiting
Haikou,Hainan,570311,China
Novartis Investigative Site
Recruiting
Chang Chun,Jilin,130021,China
Novartis Investigative Site
Recruiting
Urumqi,Xinjiang,830001,China
Novartis Investigative Site
Recruiting
Zhuzhou,Hunan,412000,China
Novartis Investigative Site
Recruiting
Linyi,Shandong,276000,China
Novartis Investigative Site
Recruiting
Beijing,100069,China
Novartis Investigative Site
Recruiting
Baotou,Inner Mongolia,014010,China
Novartis Investigative Site
Recruiting
Chengdu,Sichuan,610041,China
Novartis Investigative Site
Recruiting
Brno,63800,Czechia
Novartis Investigative Site
Recruiting
Praha 2,128 50,Czechia
Novartis Investigative Site
Recruiting
Uherske Hradiste,686 01,Czechia
Novartis Investigative Site
Recruiting
Guatemala,01010,Guatemala
Novartis Investigative Site
Recruiting
Guatemala City,01011,Guatemala
Novartis Investigative Site
Recruiting
Szekesfehervar,Fejer,8000,Hungary
Novartis Investigative Site
Recruiting
Gyula,5700,Hungary
Novartis Investigative Site
Recruiting
Ramat Gan,52621,Israel
Novartis Investigative Site
Recruiting
Haifa,3109601,Israel
Novartis Investigative Site
Recruiting
Meguro,Tokyo,153-8515,Japan
Novartis Investigative Site
Recruiting
Bunkyo ku,Tokyo,113 8655,Japan
Novartis Investigative Site
Recruiting
Kawasaki,Kanagawa,216-8511,Japan
Novartis Investigative Site
Recruiting
Chiba,2608677,Japan
Novartis Investigative Site
Recruiting
Nagoya,Aichi,457 8510,Japan
Novartis Investigative Site
Recruiting
Bunkyo ku,Tokyo,113-8431,Japan
Novartis Investigative Site
Recruiting
Yokohama-city,Kanagawa,236-0004,Japan
Novartis Investigative Site
Recruiting
Fukuoka,815-8555,Japan
Novartis Investigative Site
Recruiting
Nagoya,Aichi,457-8511,Japan
Novartis Investigative Site
Recruiting
Bunkyo-ku,Tokyo,113-8519,Japan
Novartis Investigative Site
Recruiting
Yokohama,Kanagawa,222-0036,Japan
Novartis Investigative Site
Recruiting
Gifu,500-8717,Japan
Novartis Investigative Site
Recruiting
Ichikawa,Chiba,272 8516,Japan
Novartis Investigative Site
Recruiting
Chuo ku,Tokyo,104 8560,Japan
Novartis Investigative Site
Recruiting
Kurashiki,Okayama,710-8522,Japan
Novartis Investigative Site
Recruiting
Miyazaki,889-1692,Japan
Novartis Investigative Site
Recruiting
Fukuoka city,Fukuoka,812-8582,Japan
Novartis Investigative Site
Recruiting
Fuchu-city,Tokyo,183-8561,Japan
Novartis Investigative Site
Recruiting
Suita,Osaka,565 0871,Japan
Novartis Investigative Site
Recruiting
Osaka,545-8586,Japan
Novartis Investigative Site
Recruiting
Sapporo city,Hokkaido,060 8648,Japan
Novartis Investigative Site
Recruiting
Fuchu,Tokyo,183-8524,Japan
Novartis Investigative Site
Recruiting
Iruma-gun,Saitama,350-0495,Japan
Novartis Investigative Site
Recruiting
Ono,Hyogo,675-1327,Japan
Novartis Investigative Site
Recruiting
Warszawa,04141,Poland
Novartis Investigative Site
Recruiting
Bydgoszcz,85 168,Poland
Novartis Investigative Site
Recruiting
Bydgoszcz,85-065,Poland
Novartis Investigative Site
Recruiting
Bytom,41 902,Poland
Novartis Investigative Site
Recruiting
Lodz,90-338,Poland
Novartis Investigative Site
Recruiting
Rzeszow,35 301,Poland
Novartis Investigative Site
Recruiting
Warszawa,00-874,Poland
Novartis Investigative Site
Recruiting
Wroclaw,Dolnoslaskie,52-210,Poland
Novartis Investigative Site
Recruiting
Braga,4710243,Portugal
Novartis Investigative Site
Recruiting
Leiria,2410-104,Portugal
Novartis Investigative Site
Recruiting
Lisboa,1050-034,Portugal
Novartis Investigative Site
Recruiting
Lisboa,1349-019,Portugal
Novartis Investigative Site
Recruiting
Lisboa,1649 035,Portugal
Novartis Investigative Site
Recruiting
Singapore,169608,Singapore
Novartis Investigative Site
Recruiting
Singapore,S308433,Singapore
Novartis Investigative Site
Recruiting
Singapore,119074,Singapore
Novartis Investigative Site
Recruiting
Piestany,92101,Slovakia
Novartis Investigative Site
Recruiting
Bratislava,81109,Slovakia
Novartis Investigative Site
Recruiting
Bratislava,85101,Slovakia
Novartis Investigative Site
Recruiting
Kosice,04011,Slovakia
Novartis Investigative Site
Recruiting
Cape Town,7405,South Africa
Novartis Investigative Site
Recruiting
Panorama,7500,South Africa
Novartis Investigative Site
Recruiting
Pretoria,0002,South Africa
Novartis Investigative Site
Recruiting
Stellenbosch,7600,South Africa
Novartis Investigative Site
Recruiting
Umhlanga,4320,South Africa
Novartis Investigative Site
Recruiting
Valencia,Comunidad Valenciana,46014,Spain
Novartis Investigative Site
Recruiting
Elche,Alicante,03203,Spain
Novartis Investigative Site
Recruiting
La Laguna,Santa Cruz De Tenerife,38320,Spain
Novartis Investigative Site
Recruiting
Badajoz,Extremadura,06080,Spain
Novartis Investigative Site
Recruiting
Santander,Cantabria,39008,Spain
Novartis Investigative Site
Recruiting
Madrid,28034,Spain
Novartis Investigative Site
Recruiting
Santiago De Compostela,Galicia,15706,Spain
Novartis Investigative Site
Recruiting
Valladolid,Castilla Y Leon,47012,Spain
Novartis Investigative Site
Recruiting
San Sebastian de los Reyes,Madrid,28702,Spain
Novartis Investigative Site
Recruiting
Badalona,Catalunya,08916,Spain
Novartis Investigative Site
Recruiting
Pamplona,Navarra,31008,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08003,Spain
Novartis Investigative Site
Recruiting
Vitoria Gasteiz,Pais Vasco,01009,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08035,Spain
Novartis Investigative Site
Recruiting
Vigo,Pontevedra,36200,Spain
Novartis Investigative Site
Recruiting
Songkhla,Hat Yai,90110,Thailand
Novartis Investigative Site
Recruiting
Bangkok,10400,Thailand
Novartis Investigative Site
Recruiting
Bangkok,10700,Thailand
Novartis Investigative Site
Recruiting
Chiang Mai,50200,Thailand
Novartis Investigative Site
Recruiting
Ankara,06500,Turkey
Novartis Investigative Site
Recruiting
Aydin,09100,Turkey
Novartis Investigative Site
Recruiting
Etlik Ankara,06018,Turkey
Novartis Investigative Site
Recruiting
Izmir,35620,Turkey
Novartis Investigative Site
Recruiting
Konya,42080,Turkey
Sahni Rheumatology and Therapy
Recruiting
West Long Branch,New Jersey,07764,United States
Kiren Sahni
Prisma Health
Recruiting
Columbia,South Carolina,29203,United States
Sunita Paudyal
Laketa Hillman-Daughety
Univ of Nevada School of Med
Recruiting
Las Vegas,Nevada,89102,United States
Walter Winn Chatham
Robert A Hozman MD SC
Recruiting
Skokie,Illinois,60076,United States
Robert Hozman
Epic Medical Research
Recruiting
Red Oak,Texas,75154,United States
Sunny Patel
Keck School of Medicine
Recruiting
Los Angeles,California,90033,United States
William Stohl
GNP Research
Recruiting
Hollywood,Florida,33024,United States
Mark Jaffe
Providence Medical Center
Recruiting
Burbank,California,91505,United States
Sue Chung
STAT Research Inc
Recruiting
Dayton,Ohio,45402,United States
Sanford Wolfe
Lake Cumberland Rheumatology and In
Recruiting
New Albany,Indiana,47150,United States
Kara Lay
Scott Lewis
University Of Miami
Recruiting
Miami,Florida,33136,United States
Maria Fernanda Carpintero
NYU Langone Health
Recruiting
Brooklyn,New York,11201,United States
David Goddard
Noemi Peralta
University of Colorado
Recruiting
Aurora,Colorado,80045,United States
Christopher Striebich
Prakriti Joshee
Millennium Clinical Trials
Recruiting
Westlake Village,California,91361,United States
Elvira Lindwall
Paramount Med Rsrch and Consult LLC
Recruiting
Middleburg Heights,Ohio,44130,United States
Isam Diab
Ochsner Clinic Foundation
Recruiting
Baton Rouge,Louisiana,70836,United States
Saravanan Thiagarajan
Parris and Associates Rheumatology
Recruiting
Lawrenceville,Georgia,30044,United States
Glenn Parris
Medical Center Main Campus
Recruiting
Cleveland,Ohio,44109,United States
Stanley Ballou
Clinical Res Of W Florida
Recruiting
Clearwater,Florida,33765,United States
Robert Levin
Yale University School Of Medicine
Recruiting
New Haven,Connecticut,06520,United States
Fotios Koumpouras
University of California San Diego
Recruiting
La Jolla,California,92093,United States
Chelsey J F Smith
Henry Ford Health
Recruiting
Detroit,Michigan,48202,United States
Alireza Meysami
Accurate Clinical Research Research
Recruiting
Baytown,Texas,77521,United States
Sabeen Najam
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.